[18F]FDG PET/MRI在复发性胃癌分期中较MDCT的附加价值
本研究纳入50例组织学或临床确诊的复发性胃癌患者,均行MDCT和[18F]FDG PET/MRI。两位阅片者独立评估TNM分期及可切除性。结果显示联合PET/MRI可显著提高M分期诊断准确率及可切除性评估的AUC值,而T、N分期准确率无显著差异。
要点
- 联合PET/MRI可显著提高复发性胃癌M分期的诊断准确率。
- 联合PET/MRI可提高可切除性评估的AUC值,但仅一位阅片者差异有统计学意义。
- T、N分期准确率在联合PET/MRI与单独MDCT间无显著差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) can improve the diagnostic performance of TNM staging and help in making an accurate decision regarding resectability in patients with recurrent gastric cancer compared to multi-detector computed tomography (MDCT).
METHODS: Fifty patients with histologically (n = 31) or clinically (n = 19) confirmed recurrent gastric cancer underwent both MDCT and [18F]FDG PET/MRI. Two radiologists independently assessed TNM staging using MDCT with and without [18F]FDG PET/MRI and scored resectability using a 5-point confidence scale. Diagnostic performance as assessed by radiologists was compared using McNemar's test and receiver operating characteristic curve analysis.
RESULTS: Of the 50 patients, pathologic T and N staging was available in seven and six patients, respectively. Diagnostic accuracies for T and N staging were not significantly different between MDCT with and without [18F]FDG PET/MRI for both reviewers (p > 0.05). However, for M staging, diagnostic accuracy was significantly improved when 18F-FDG PET/MRI was added to MDCT alone (68.0% [34/50] to 90.0% [45/50] for reviewer 1 [p = 0.001] and 66.0% [33/50] to 96.0% [46/50] for reviewer 2 [p < 0.001]). Regarding the resectability of recurrent gastric cancers, the addition of [18F]FDG PET/MRI increased the area under the curve values for both reviewers (from 0.860 to 0.989 for reviewer 1 and from 0.778 to 0.898 for reviewer 2), with a statistical significance for reviewer 2 (p = 0.002).
CONCLUSION: Compared to MDCT alone, MDCT plus [18F]FDG PET/MRI can improve the diagnostic accuracy for evaluating preoperative M staging as well as resectability for recurrent gastric cancers.
KEY POINTS: • [18F]FDG PET/MRI can improve diagnostic accuracy for preoperative M staging in patients with recurrent gastric cancers. • [18F]FDG PET/MRI can improve diagnostic accuracy for determining resectability in patients with recurrent gastric cancers. • [18F]FDG PET/MRI can provide critical clues for management options for recurrent gastric cancers.
引用
- Yoon I, Bae JS, Yoo J, et al. Added value of [18F]FDG PET/MRI over MDCT alone in the staging of recurrent gastric cancer. Eur Radiol. 2021. PMID: 33768290. doi:10.1007/s00330-021-07839-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。